Communication: Antimicrobial activity of SMAP28 with a targeting domain for Porphyromonas gingivalis

Probiotics and Antimicrobial Proteins

Volumn 2, Issue 1, 2010, Pages 21-25

  Bratt, Carol L ^a   Kohlgraf, Karl G ^a   Yohnke, Katie ^a   Kummet, Colleen ^a   Dawson, Deborah V ^a,b   Brogden, Kim A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Periodontal disease; Porphyromonas gingivalis; SMAP28; Targeted antimicrobial activity

Indexed keywords

\SMAP 28; ANTIBIOTIC AGENT; ANTIBODY; ANTIINFECTIVE AGENT; LIGAND; PEPTIDE; PEPTIDE ZS37 37; PEPTIDE ZS37 38; PHEROMONE; POLYPEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; PROLINE RICH PROTEIN; PROPYLGLUTAMINYLGLYCYLPROPYLPROPYLGLYCINE; SMAP 28; UNCLASSIFIED DRUG; ZS 37 37; ZS 37 38;

AGGREGATIBACTER ACTINOMYCETEMCOMITANS; AMINO TERMINAL SEQUENCE; ANTIMICROBIAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG DESIGN; DRUG SPECIFICITY; ESCHERICHIA COLI; FUSOBACTERIUM NUCLEATUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; FUSOBACTERIUM NUCLEATUM; PORPHYROMONAS GINGIVALIS; STAPHYLOCOCCUS AUREUS;

EID: 77953869977     PISSN: 18671306     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12602-009-9028-5     Document Type: Article

References (11)

1. Gleckman RA, Borrego F (1997) Adverse reactions to antibiotics. Clues for recognizing, understanding, and avoiding them. Postgrad Med 101: 97-98, 101-104, 107-108.
2. Kalfa VC, Jia HP, Kunkle RA, McCray PB Jr, Tack BF, Brogden KA (2001) Congeners of SMAP29 kill ovine pathogens and induce ultrastructural damage in bacterial cells. Antimicrob Agents Chemother 45: 3256-3261.
3. Skerlavaj B, Benincasa M, Risso A, Zanetti M, Gennaro R (1999) SMAP-29: a potent antibacterial and antifungal peptide from sheep leukocytes. Fed Eur Biol Sci Lett 463: 58-62.
4. Weistroffer PL, Joly S, Srikantha R, Tack BF, Brogden KA, Guthmiller JM (2008) SMAP29 congeners demonstrate activity against oral bacteria and reduced toxicity against oral keratinocytes. Oral Microbiol Immunol 23: 89-95.
5. Franzman MR, Burnell KK, Dehkordi-Vakil FH, Guthmiller JM, Dawson DV, Brogden KA (2009) Targeted antimicrobial activity of a specific IgG-SMAP28 conjugate against Porphyromonas gingivalis in a mixed culture. Int J Antimicrob Agents 33: 14-20.
6. Kataoka K, Amano A, Kawabata S, Nagata H, Hamada S, Shizukuishi S (1999) Secretion of functional salivary peptide by Streptococcus gordonii which inhibits fimbria-mediated adhesion of Porphyromonas gingivalis. Infect Immun 67: 3780-3785.
7. Kataoka K, Amano A, Kuboniwa M, Horie H, Nagata H, Shizukuishi S (1997) Active sites of salivary proline-rich protein for binding to Porphyromonas gingivalis fimbriae. Infect Immun 65: 3159-3164.
8. Wang G, Li X, Wang Z (2009) APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res 37: D933-D937.
9. Wang Z, Wang G (2004) APD: the antimicrobial peptide database. Nucleic Acids Res 32: D590-D592.
10. Qiu XQ, Wang H, Lu XF, Zhang J, Li SF, Cheng G, Wan L, Yang L, Zuo JY, Zhou YQ, Wang HY, Cheng X, Zhang SH, Ou ZR, Zhong ZC, Cheng JQ, Li YP, Wu GY (2003) An engineered multidomain bactericidal peptide as a model for targeted antibiotics against specific bacteria. Nat Biotechnol 21: 1480-1485.
11. Qiu XQ, Zhang J, Wang H, Wu GY (2005) A novel engineered peptide, a narrow-spectrum antibiotic, is effective against vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 49: 1184-1189.